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Background: Acute-phase patients sometimes require hemodialysis therapy without vascular access (VA) present
on admission. These patients require VA creation to continue hemodialysis after discharge. The risk of early VA
failure in acute-phase conditions is considered high due to the unstable nature of the patients’ condition. Hence,
optimal timing of VA creation is not established.
Methods: This retrospective study included patients who had VA (arteriovenous fistula or graft) created between
May 2010 and July 2016.
Results: During this study, 913 VA creations were performed among 804 patients. Of the included, 435 were
acute-phase patients (275 men, 160 women). The average age was 67.4 ± 14.7 years. The causes of admission were
exacerbation of renal failure (274 patients, 63.0 %), heart disease (61 patients, 14.0 %), infectious disease (30 patients,
6.9 %), and malignancy (15 patients, 3.4 %). Early VA failure occurred in 53 patients (12.2 %). There was no difference
in causes of admission between patients with and without VA failure. Serum albumin level was significantly lower
(2.7 ± 0.8 g/dL vs. 3.0 ± 0.6 g/dL, P < 0.01) in the early VA failure group than in the without early failure group.
Albumin level was associated with early VA failure (odds ratio 0.4723, 95 % confidence interval 0.2744–0.8130,
P < 0.01). Assessing only patients with arteriovenous fistula, the serum albumin level was significantly lower
(2.6 ± 0.7 g/dL vs. 3.1 ± 0.6 g/dL, P < 0.01) in the early VA failure group than in the without early failure group.
Conclusions: When we perform VA creation in acute-phase patients, hypoalbuminemia is associated with the risk
of early VA failure. The status of the patient is an important factor to consider when creating VA.
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Patients, especially those with chronic kidney disease, who
are admitted to the hospital with acute-phase illness, such
as cardiovascular disease, infectious disease, and stroke,
sometimes complicate with acute kidney injury and transi-
tion into end-stage renal disease (ESRD), which requires
dialysis therapy. Furthermore, ESRD patients sometimes
complicate with acute-phase illness and are admitted to
the hospital with vascular access (VA) occlusion as a result.
As our hospital has an emergency unit, many patients, with
various diseases, are referred to our hospital without usable
VA. VA must be created to continue hemodialysis (HD).
However, the patient state during the acute phase is* Correspondence: zhangren_at_23@yahoo.co.jp
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blood pressure, hypercoagulation, and intravascular
volume depletion. Hence, the risk of early VA failure
during the acute-phase condition is considered to be
increased. Furthermore, patients with complications, such
as cardiovascular and cerebrovascular diseases, often
already demonstrate advanced atherosclerosis. Hence, the
maturation of VA may be poor. Clinically, we decide the
timing of VA creation by taking general condition, such as
blood pressure, fluid volume, and presence of infection,
into consideration. However, there is no established
evidence showing what condition is optimal for VA
creation. Some studies report that a small-diameter artery
or vein is a disadvantage for VA maturation. Low volume
of VA flow is also a reported disadvantage. However,
regarding patients with VA placed during the acute phase,le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Baseline characteristics of patients receiving VA
placement (n = 435)
Parameter




Atrial fibrillation (%) 9.2
Primary cause of admission
Exacerbation of renal failure (%) 63.0
Heart disease (%) 14.0
Heart failure (%) 10.6
Coronary artery disease (%) 2.3
Infectious disease (%) 6.9
Malignancy (%) 3.4
Cephalopathy (%) 2.8
Cerebral infarction (%) 0.7
Intracranial hemorrhage (%) 0.9
Peripheral artery disease (%) 0.7
Aortic disease (%) 0.9
Others (%) 8.3
AVF (%) 76.1
Early failure (%) 12.2
VA vascular access, AVF arteriovenous fistula
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maturation.
We herein assessed the factors of early VA failure in
patients with VA placement during the acute phase.
Methods
Patients and data collection
This is a retrospective study. We included patients who had
VA created between May 2010 and July 2016. Primary cause
of admission, past history, physical examination, and labora-
tory data were collected from medical records. Blood pres-
sure was defined as the reading immediately before VA
creation. Laboratory data were defined as the most recent
(within 1 week) prior to the first VA creation. Inclusion
criteria consisted of the following: adult patient with VA
creation performed, VA not available on admission, VA
placed during hospitalization, hospitalization length of stay
more than 3 days, and VA used at least once in our hospital.
Because in our hospital the period of hospitalization for only
VA creation is usually within 3 days, longer hospitalization
means that there is other reason to continue hospitalization.
Acute-phase illness means various ones which require
admission other than VA creation. Exclusion criteria in-
cluded patient death during hospitalization.
Vascular access creation
According to past reports, VA was created with vascular
mapping by ultrasonography. An artery and a vein greater
than 1.5 mm in diameter were used to create arterioven-
ous fistulas (AVF). If AVF creation was difficult, arterio-
venous grafts (AVG) were created. An operating surgeon
or instructor had more than 10 years of experience.
Definition of early vascular access failure
Early VA failure was defined as a case in which VA cre-
ation surgery was required two or more times during one
hospitalization because first VA did not become usable.
Statistical analysis
Baseline characteristics were presented descriptively and
were tested using Student’s t test or χ2 test. Logistic re-
gression analysis and receiver operative characteristic
(ROC) curve were used to evaluate early VA failure after




During the period of this study, 913 VA creations in 804
patients were performed. Of them, 452 patients had VA
creations performed during acute-phase condition. Of the
452 patients, 17 died before discharge. The remaining 435
patients (275 men and 160 women) were assessed. The
average age was 67.4 ± 14.7 years. Table 1 depicts thebaseline profile of all patients. The most frequent primary
cause of admission was exacerbation of renal failure. Early
VA failure occurred in 12.2 % of patients.
Characteristics of patients with and without early failure
of vascular access
Table 2 is a comparison of patients with and without early
VA failure. There was no significant difference between the
patients with and without VA failure in age, past history,
primary cause of admission, medication, or cardiac func-
tion. However, the percentage of male was significantly
lower in the early VA failure group. Further, diastolic blood
pressure (DBP) was significantly lower in the early VA
failure group than in the without early VA failure group.
Serum albumin level (ALB) was significantly lower and C-
reactive protein (CRP) higher in the early VA failure group.
The impact of serum ALB levels on early VA failure
Table 2 displays the association between early VA failure
and DBP, serum ALB, or CRP. Table 3 shows non-adjusted
odds ratios after logistic regression analysis using early VA
failure as the objective variable. Table 4 illustrates odds
ratio adjusted by age, gender, past history of diabetes, DBP,
serum ALB, creatinine (Cr), CRP, and AVF. Only the level
of serum ALB showed significant association with early
VA failure.






Age (years) 66.9 ± 14.6 70.7 ± 15.6 0.0819
Male (%) 65.2 49.1 0.0225*
Diabetes (%) 45.0 52.8 0.2854
Hypertension (%) 68.3 62.3 0.3770
Atrial fibrillation (%) 8.3 15.1 0.1128
Primary cause of admission
Exacerbation of CRF (%) 64.1 54.7 0.1832
Heart disease (%) 13.6 17.0 0.5081
Heart failure (%) 9.9 15.1 0.2535
Coronary artery disease (%) 2.4 1.9 0.8309
Infectious disease (%) 6.5 9.4 0.4366
Malignancy (%) 3.4 3.8 0.8898
Cephalopathy (%) 2.6 3.8 0.6302
Cerebral infarction (%) 0.5 1.9 0.2611
Intracranial hemorrhage (%) 1.0 0.0 0.4542
Peripheral artery disease (%) 0.5 1.9 0.2611
Aortic disease (%) 1.0 0.0 0.4542
Others (%) 8.1 9.4 0.7440
Warfarin (%) 9.7 11.3 0.7086
Antiplatelet agent (%) 31.2 32.1 0.8919
Statin (%) 32.2 30.2 0.7687
ACEi or ARB (%) 46.9 41.5 0.4642
Beta blocker (%) 34.0 34.0 0.9921
CCB (%) 60.0 60.4 0.9523
LVEF (%) 55.6 ± 12.9 56.5 ± 12.7 0.7022
SBP (mmHg) 138.6 ± 24.2 132.1 ± 23.7 0.0671
DBP (mmHg) 75.1 ± 16.2 69.1 ± 17.3 0.0119*
WBC (103/μL) 7.2 ± 3.2 8.0 ± 3.5 0.0870
Hb (g/dL) 9.8 ± 1.7 9.7 ± 1.9 0.6712
PLT (104/μL) 19.2 ± 7.8 19.7 ± 8.3 0.6834
TP (g/dL) 6.1 ± 0.9 5.9 ± 1.0 0.1570
ALB (g/dL) 3.0 ± 0.6 2.7 ± 0.8 0.0002**
BUN (mg/dL) 68.5 ± 28.7 63.0 ± 34.2 0.2035
Cr (mg/dL) 7.3 ± 3.0 6.4 ± 2.4 0.0414*
eGFR (mL/min/1.7 m2) 7.3 ± 3.9 7.6 ± 3.6 0.6209
AST (IU/L) 23.2 ± 20.0 25.8 ± 24.9 0.3891
ALT (IU/L) 18.9 ± 21.3 17.7 ± 21.4 0.7076
CRP (mg/dL) 2.2 ± 3.3 3.2 ± 4.4 0.0390*
APTT 30.2 ± 9.7 31.2 ± 8.1 0.5918
PT-INR 1.16 ± 0.40 1.16 ± 0.20 0.9994
AVF (%) 77.5 66.0 0.0671
VA vascular access, CRF chronic renal failure, ACEi angiotensin-converting enzyme
inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker, LVEF left
ventricular ejection fraction, SBP systolic blood pressure, DBP diastolic blood
pressure, WBC white blood cell, Hb hemoglobin, PLT platelet, TP total protein,
ALB albumin, BUN blood urea nitrogen, Cr creatinine, eGFR estimated glomerular
filtration rate, AST aspartate aminotransferase, ALT alanine transaminase, CRP C-
reactive protein, APTT activated partial thromboplastin time, PT-INR international
normalized ratio of prothrombin time, AVF, arteriovenous fistula
*P < 0.05; **P < 0.01
Table 3 Odds ratio for early VA failure with evaluated
parameters (non-adjusted)
Parameter Odds ratio 95 % CI P value
DBP (mmHg) 0.9770 0.9593–0.9950 0.0124*
ALB (g/dL) 0.4287 0.2709–0.6784 0.0003**
Cr (mg/dL) 0.8929 0.8003–0.9961 0.0424*
CRP (mg/dL) 1.0728 1.0017–1.1489 0.0447*
AVF 0.5649 0.3048–1.0471 0.0697
VA vascular access, CI confidence interval, DBP diastolic blood pressure, ALB
albumin, Cr creatinine, CRP C-reactive protein, AVF arteriovenous fistula
*P < 0.05; **P < 0.01
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The data in Tables 3 and 4 support the association
between early VA failure and serum ALB, so a ROC
curve was assessed to detect early VA failure. Figure 1
illustrates the ROC curve of serum ALB. From this
finding, we considered serum ALB less than 2.82 g/dL to
be the cutoff level to predict early VA failure.
Analyses for only AVF
Next, we assessed only patients with AVF because the
characteristics of AVG failure may be different from the
ones in AVF. We assessed for majority of our patients with
AVF (n = 331). Table 5 is a comparison of patient-created
AVF with and without early VA failure. There was no
significant difference between the patients with and
without VA failure in age, past history, primary cause of
admission, medication, or cardiac function. However, the
level of ALB was significantly lower and white blood cell
count higher in the early VA failure group. Table 6 shows
non-adjusted and Table 7 shows adjusted odds ratios
using early VA failure as the objective variable. Table 7
illustrates odds ratio adjusted by age, gender, past history
of diabetes, white blood cell count, and serum ALB. Only
the level of serum ALB showed significant association
with early VA failure in patients with AVF.
Discussion
In this study, we evaluated the association between early
VA failure and serum ALB level in acute-phase illnessTable 4 Odds ratio for early VA failure with evaluated
parameters (adjusted)
Parameter Odds ratio 95 % CI P value
DBP (mmHg) 0.9866 0.9668–1.0068 0.1924
ALB (g/dL) 0.4723 0.2744–0.8130 0.0068**
Cr (mg/dL) 1.0270 0.8977–1.1748 0.6980
CRP (mg/dL) 1.0444 0.9639–1.1316 0.2883
AVF 0.6260 0.3239–1.2097 0.1634
Adjusted by age, gender, diabetes, DBP, ALB, Cr, CRP, and AVF
VA vascular access, CI confidence interval, DBP diastolic blood pressure,
ALB albumin, Cr creatinine, CRP C-reactive protein, AVF arteriovenous fistula
**P < 0.01
Fig. 1 The ROC curve for early vascular access failure using serum ALB
levels in all patients. The AUC of ALB is 0.652 and the cutoff value is
2.82 g/dL. ROC receiver operative characteristic, ALB albumin, AUC area
under the curve, TPF true positive fraction, FPF false positive fraction







Age (years) 66.4 ± 15.0 67.8 ± 17.1 0.5903
Male (%) 68.2 57.1 0.1864
Diabetes (%) 45.6 48.6 0.7393
Hypertension (%) 70.6 71.4 0.9197
Atrial fibrillation (%) 8.5 11.4 0.5551
Primary cause of admission
Exacerbation of CRF (%) 65.9 62.9 0.7221
Heart disease (%) 13.9 14.3 0.9440
Heart failure (%) 10.5 14.3 0.4933
Coronary artery disease (%) 2.0 0.0 0.3953
Infectious disease (%) 5.4 8.6 0.4464
Malignancy (%) 4.1 5.7 0.6444
Cephalopathy (%) 3.0 2.9 0.9522
Cerebral infarction (%) 0.7 2.9 0.1978
Intracranial hemorrhage (%) 1.0 0.0 0.5496
Peripheral artery disease (%) 0.7 2.9 0.1978
Aortic disease (%) 1.4 0.0 0.4890
Others (%) 5.7 2.9 0.4764
Warfarin (%) 10.5 11.4 0.8620
Antiplatelet agent (%) 27.0 22.9 0.5975
Statin (%) 32.4 22.9 0.2485
ACEi or ARB (%) 49.0 45.7 0.7142
Beta blocker (%) 33.1 25.7 0.3765
CCB (%) 63.5 71.4 0.3552
LVEF (%) 56.0 ± 12.5 56.8 ± 13.3 0.7316
SBP (mmHg) 138.9 ± 24.7 132.6 ± 23.4 0.1568
DBP (mmHg) 75.5 ± 16.6 71.1 ± 14.5 0.1309
WBC (103/μL) 7.2 ± 3.2 8.4 ± 3.6 0.0376*
Hb (g/dL) 9.7 ± 1.8 9.7 ± 1.7 0.8780
PLT (104/μL) 19.2 ± 8.1 21.2 ± 8.9 0.1666
TP (g/dL) 6.1 ± 0.9 5.8 ± 0.9 0.0540
ALB (g/dL) 3.1 ± 0.6 2.6 ± 0.7 0.0006**
BUN (mg/dL) 70.1 ± 29.2 60.2 ± 27.8 0.0578
Cr (mg/dL) 7.6 ± 3.0 6.9 ± 2.6 0.1933
eGFR (mL/min/1.7 m2) 7.1 ± 3.8 7.4 ± 3.5 0.6445
AST (IU/L) 22.6 ± 20.3 21.9 ± 12.0 0.8438
ALT (IU/L) 18.6 ± 20.9 15.6 ± 15.9 0.4238
CRP (mg/dL) 2.3 ± 3.4 2.7 ± 4.6 0.5259
APTT 30.7 ± 14.2 28.7 ± 4.7 0.4961
PT-INR 1.17 ± 0.42 1.14 ± 0.25 0.6554
VA vascular access, CRF chronic renal failure, ACEi angiotensin-converting enzyme
inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker, LVEF left
ventricular ejection fraction, SBP systolic blood pressure, DBP diastolic blood
pressure, WBC white blood cell, Hb hemoglobin, PLT platelet, TP total protein,
ALB albumin, BUN blood urea nitrogen, Cr creatinine, eGFR estimated glomerular
filtration rate, AST aspartate aminotransferase, ALT Alanine transaminase,
CRP C-reactive protein, APTT activated partial thromboplastin time, PT-INR
international normalized ratio of prothrombin time
*P < 0.05; **P < 0.01
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dialysis therapy. On the other hand, there was no rela-
tion between early VA failure and the type of acute-
phase illness. We opine that the more important point
for VA creation is a stable condition, rather than cause
of admission or type of medicine. In other words, to
decide the timing of VA creation, it is more important
to confirm that the patient’s condition is stable.
Past reports assessed early VA failure regardless of the
presence of acute-phase illness. Despite better patient
condition due to the absence of acute-phase illness, 20
to 60 % early VA failure was reported [1, 2]. The preva-
lence of early VA failure in our study was lower than
that of the past reports despite worse patient condition.
In the previous reports, the diameter of the artery or
vein is associated with the patency and maturation of VA
[3–6]. In this study, the diameters of the artery and vein
were not assessed; however, our hospital creates AVF
when the diameters of the artery and vein are more than
1.5 to 2 mm with mapping by ultrasonography [7, 8]. As
this study is from a single center, there seems to be little
variability of the diameter of the artery and vein used for
VA creation.
Previous reports suggested that the level of CRP, the
presence of diabetes mellitus (DM), and hypertension
(HT) are associated with early VA failure [1, 2, 9].
However, our results did not show significant association
between early VA failure and DM or HT. As many
elderly patients included in our study were already
diagnosed with advanced atherosclerotic diseases, the
effects of DM and HT were likely diminished. There
have been no reports assessing appropriate timing of VA
creation during acute-phase illness. Our study is consid-
ered to be extremely clinically useful and meaningful.
Table 6 Odds ratio for early VA (AVF) failure with evaluated
parameters (non-adjusted)
Parameter Odds ratio 95 % CI P value
WBC (103/μL) 1.0950 1.0024–1.1961 0.0441*
ALB (g/dL) 0.3849 0.2187–0.6772 0.0009**
VA vascular access, AVF arteriovenous fistula, CI confidence interval, WBC white
blood cell, ALB albumin
*P < 0.05; **P < 0.01
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reduction, is considered to be a factor in occlusion of VA.
There was a previous report which described that hypoal-
buminemia was a cause of VA failure [10]. However, this
report did not focus on the patients’ state, different from
our study which focused on acute-phase patients. There is
another report which described that hyperinsulinism is a
cause of VA failure [11]. However, this report did not focus
on the patients’ status, as well. Furthermore, inflammation
may induce excessive coagulation of blood. Since hypoal-
buminemia progresses during times of inflammation, it
may also be considered an indication of inflammation.
When hypoalbuminemia and/or inflammation are present,
unphysiological blood flow, such as present in a shunt,
seems likely to occlude before maturation. In that sense,
adjusting the timing of VA creation to when the influence
of the acute illness has faded might be effective in order to
prevent early VA failure. However, when patients are
complicated with dialysis catheter-related blood stream
infections and require VA creation as soon as possible, a
heparin infusion or supporting intravascular volume may
be choices to prevent excessive coagulation.
This study has some limitations. First, this study is a
single center study in Japan. Recently, the number of
elderly patients in Japan initiated into dialysis therapy is
increasing [12], and the vascular state of these patients is
poor due to age or other complications. This result may be
difficult to apply in other countries where a majority of pa-
tients initiated into dialysis therapy are younger. However,
despite adverse patient conditions, our results were super-
ior to other reports on early VA failure rate. In addition,
although using a single facility is a limitation, the fact of less
variation in operator competence may be a benefit.
Second, although we included acute-phase illness, we did
not assess the severity of illness by using acute physiologyTable 7 Odds ratio for early VA (AVF) failure with evaluated
parameters (adjusted)
Parameter Odds ratio 95 % CI P value
WBC (103/μL) 1.0798 0.9835–1.1855 0.1073
ALB (g/dL) 0.4198 0.2339–0.7533 0.0036**
Adjusted by age, gender, diabetes, WBC, and ALB
VA vascular access, AVF arteriovenous fistula, CI confidence interval, WBC white
blood cell, ALB albumin
**P < 0.01and chronic health evaluation (APACHE) II scores [13] or
sequential organ failure assessment (SOFA) scores [14].
Since not all the patients were admitted to an intensive care
unit, this could affect the results.
Conclusions
When performing VA creation in acute-phase illness
patients, hypoalbuminemia is associated with the risk of
early VA failure. We must consider a factor in the serum
ALB level when deciding the timing of VA creation.
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